Table 2 CLL-directed treatment.
Treatment | Category | Number | Percentage | Missing |
|---|---|---|---|---|
CLL treatment status | Treated | 547 | 58.1% | 0 (0%) |
Untreated | 394 | 41.9% | ||
Treated status in last 12 months | Treated | 432 | 46% | 2 (0.2%) |
Untreated | 507 | 54% | ||
Treatment status for CLL at the time of COVID-19 | Treated | 320 | 34% | 1 (0.1%) |
Untreated | 620 | 66% | ||
Management of CLL treatment | Continued as planned | 104 | 32.7% | (0.6%) |
Replaced with other | 2 | 0.6% | ||
Stopped | 212 | 66.7% | ||
Total prior lines of treatment | 1 | 275 | 50.7% | 5 (0.9%) |
2 | 149 | 27.5% | ||
3 | 60 | 11.1% | ||
4 | 33 | 6.1% | ||
>4 | 25 | 4.6% | ||
Treatment at the time of COVID-19 | BTKi | 179 | 56.3% | 2 (0.6%) |
Venetoclax | 34 | 10.7% | ||
Venetoclax +Anti-CD20 | 17 | 5.3% | ||
PI3K inhibitors | 10 | 3.1% | ||
PI3K inhibitors + Anti-CD20 | 3 | 0.9% | ||
Anti-CD20 | 8 | 2.5% | ||
Chemotherapy | 22 | 6.9% | ||
Chemoimmunotherapy | 29 | 9.1% | ||
BTKi + Venetoclax | 7 | 2.2% | ||
BTKi + Venetoclax + Anti-CD20 | 2 | 0.6% | ||
Steroids only | 7 | 2.2% |
